March 2021 Simoa® Publications:
Neurology: General
Serum Glial Fibrillary Acidic Protein: a Neuromyelitis Optica Spectrum Disorder Biomarker
Aktas O, et al.
Ann Neurol. 2021
A comprehensive data-driven analysis framework for detecting impairments in brain function networks with resting state fMRI in HIV-infected individuals on cART
Anteraper SA, et al.
Journal of neurovirology. 2021
Neurological symptoms and blood neurofilament light levels
Barro C and Zetterberg H
Acta neurologica Scandinavica. 2021
Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation
Chatterjee P, et al.
International journal of molecular sciences. 2021;22:2931
Biological variation of serum neurofilament light chain
Hviid CVB, et al.
Clin Chem Lab Med. 2021
AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy
Kagiava A, et al
Gene Ther. 2021
Neurofilament light chain as novel blood biomarker of disturbed neuroaxonal integrity in patients with ketamine dependence
Liu YL, et al.
World J Biol Psychiatry. 2021:1-28
Cortical microstructural correlates of plasma neurofilament light chain in Huntington’s disease
Sampedro F, et al.
Parkinsonism Relat Disord. 2021 Mar 20;85:91-94
Heterogeneity in α-synuclein fibril activity correlates to disease phenotypes in Lewy body dementia
Sokratian A, et al.
Acta neuropathologica. 2021;141:547-564
Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases
Thompson AGB, et al.
Mol Psychiatry (2021).
Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy
Weinhofer I, et al.
Nat Commun 12, 1816 (2021)
March 2021 Simoa® Publications in Other Therapeutic Areas
